ALHC vs. CYTK: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ALHC and CYTK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
CYTK’s market capitalization of 4.14 billion USD is significantly greater than ALHC’s 2.68 billion USD, highlighting its more substantial market valuation.
ALHC’s beta of 1.22 points to significantly higher volatility compared to CYTK (beta: 0.59), suggesting ALHC has greater potential for both gains and losses relative to market movements.
| Symbol | ALHC | CYTK |
|---|---|---|
| Company Name | Alignment Healthcare, Inc. | Cytokinetics, Incorporated |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Healthcare Plans | Biotechnology |
| CEO | John E. Kao | Robert I. Blum |
| Price | 13.57 USD | 34.66 USD |
| Market Cap | 2.68 billion USD | 4.14 billion USD |
| Beta | 1.22 | 0.59 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | March 26, 2021 | April 30, 2004 |
| ADR | No | No |
Historical Performance
This chart compares the performance of ALHC and CYTK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ALHC
-81.24%
Medical - Healthcare Plans Industry
- Max
- 13.94%
- Q3
- 13.62%
- Median
- 11.42%
- Q1
- 7.74%
- Min
- 6.98%
ALHC has a negative Return on Equity of -81.24%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
CYTK
801.26%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
CYTK’s Return on Equity of 801.26% is exceptionally high, placing it well beyond the typical range for the Biotechnology industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Return on Invested Capital
ALHC
-15.02%
Medical - Healthcare Plans Industry
- Max
- 15.50%
- Q3
- 7.12%
- Median
- 5.48%
- Q1
- -3.47%
- Min
- -15.02%
ALHC has a negative Return on Invested Capital of -15.02%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
CYTK
-49.75%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
CYTK has a negative Return on Invested Capital of -49.75%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
Net Profit Margin
ALHC
-3.02%
Medical - Healthcare Plans Industry
- Max
- 3.23%
- Q3
- 2.62%
- Median
- 1.70%
- Q1
- 1.27%
- Min
- 1.22%
ALHC has a negative Net Profit Margin of -3.02%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
CYTK
-3,201.47%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
CYTK has a negative Net Profit Margin of -3,201.47%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin
ALHC
-2.19%
Medical - Healthcare Plans Industry
- Max
- 4.30%
- Q3
- 3.77%
- Median
- 2.61%
- Q1
- 1.60%
- Min
- -1.64%
ALHC has a negative Operating Profit Margin of -2.19%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
CYTK
-2,943.30%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
CYTK has a negative Operating Profit Margin of -2,943.30%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | ALHC | CYTK |
|---|---|---|
| Return on Equity (TTM) | -81.24% | 801.26% |
| Return on Assets (TTM) | -10.12% | -48.67% |
| Return on Invested Capital (TTM) | -15.02% | -49.75% |
| Net Profit Margin (TTM) | -3.02% | -3201.47% |
| Operating Profit Margin (TTM) | -2.19% | -2943.30% |
| Gross Profit Margin (TTM) | 11.57% | -1359.51% |
Financial Strength
Current Ratio
ALHC
1.69
Medical - Healthcare Plans Industry
- Max
- 1.91
- Q3
- 1.63
- Median
- 1.43
- Q1
- 0.85
- Min
- 0.78
ALHC’s Current Ratio of 1.69 is in the upper quartile for the Medical - Healthcare Plans industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
CYTK
5.99
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
CYTK’s Current Ratio of 5.99 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
ALHC
0.07
Medical - Healthcare Plans Industry
- Max
- 1.06
- Q3
- 0.86
- Median
- 0.75
- Q1
- 0.66
- Min
- 0.66
At 0.07, ALHC’s Debt-to-Equity Ratio is unusually low for the Medical - Healthcare Plans industry. This highlights a conservative capital structure, suggesting the company prioritizes financial stability over aggressive growth funded by debt.
CYTK
-2.97
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
CYTK has a Debt-to-Equity Ratio of -2.97, which indicates negative shareholder equity where liabilities exceed assets. This is a critical sign of financial distress.
Interest Coverage Ratio
ALHC
-2.98
Medical - Healthcare Plans Industry
- Max
- 6.23
- Q3
- 6.23
- Median
- 5.19
- Q1
- 4.64
- Min
- 3.18
ALHC has a negative Interest Coverage Ratio of -2.98. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
CYTK
-6.14
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
CYTK has a negative Interest Coverage Ratio of -6.14. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | ALHC | CYTK |
|---|---|---|
| Current Ratio (TTM) | 1.69 | 5.99 |
| Quick Ratio (TTM) | 1.69 | 5.99 |
| Debt-to-Equity Ratio (TTM) | 0.07 | -2.97 |
| Debt-to-Asset Ratio (TTM) | 0.01 | 0.63 |
| Net Debt-to-EBITDA Ratio (TTM) | 10.90 | -1.39 |
| Interest Coverage Ratio (TTM) | -2.98 | -6.14 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ALHC and CYTK. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ALHC
0.00%
Medical - Healthcare Plans Industry
- Max
- 3.88%
- Q3
- 1.78%
- Median
- 0.73%
- Q1
- 0.00%
- Min
- 0.00%
ALHC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
CYTK
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
CYTK currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
ALHC
0.00%
Medical - Healthcare Plans Industry
- Max
- 63.88%
- Q3
- 29.91%
- Median
- 12.57%
- Q1
- 0.00%
- Min
- 0.00%
ALHC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
CYTK
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
CYTK has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ALHC | CYTK |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio
ALHC
-28.99
Medical - Healthcare Plans Industry
- Max
- 18.17
- Q3
- 17.32
- Median
- 15.48
- Q1
- 13.55
- Min
- 12.84
ALHC has a negative P/E Ratio of -28.99. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
CYTK
-6.68
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
CYTK has a negative P/E Ratio of -6.68. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
Forward P/E to Growth Ratio
ALHC
-0.99
Medical - Healthcare Plans Industry
- Max
- 1.41
- Q3
- 1.09
- Median
- 0.85
- Q1
- 0.79
- Min
- 0.60
ALHC has a negative Forward PEG Ratio of -0.99. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.
CYTK
11.70
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
CYTK’s Forward PEG Ratio of 11.70 is exceptionally high for the Biotechnology industry. This suggests its stock price is very high relative to its expected earnings growth, signaling significant overvaluation risk.
Price-to-Sales Ratio
ALHC
0.89
Medical - Healthcare Plans Industry
- Max
- 0.94
- Q3
- 0.64
- Median
- 0.43
- Q1
- 0.27
- Min
- 0.16
ALHC’s P/S Ratio of 0.89 is in the upper echelon for the Medical - Healthcare Plans industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
CYTK
215.39
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
With a P/S Ratio of 215.39, CYTK trades at a valuation that eclipses even the highest in the Biotechnology industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio
ALHC
24.30
Medical - Healthcare Plans Industry
- Max
- 4.08
- Q3
- 3.83
- Median
- 2.63
- Q1
- 1.74
- Min
- 0.96
At 24.30, ALHC’s P/B Ratio is at an extreme premium to the Medical - Healthcare Plans industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
CYTK
-15.42
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
Valuation at a Glance
| Symbol | ALHC | CYTK |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -28.99 | -6.68 |
| Forward PEG Ratio (TTM) | -0.99 | 11.70 |
| Price-to-Sales Ratio (P/S, TTM) | 0.89 | 215.39 |
| Price-to-Book Ratio (P/B, TTM) | 24.30 | -15.42 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 140.75 | -10.11 |
| EV-to-EBITDA (TTM) | -55.82 | -9.41 |
| EV-to-Sales (TTM) | 0.75 | 252.72 |